Novel Extended-Release Multiple-Unit System of Imidafenacin Prepared by Fluid-Bed Coating Technique
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Taek Hwan | - |
dc.contributor.author | Im, Sung Hyun | - |
dc.contributor.author | Goh, Min Su | - |
dc.contributor.author | Lee, Eun Seok | - |
dc.contributor.author | Ho, Myoung Jin | - |
dc.contributor.author | Kim, Chang Hyun | - |
dc.contributor.author | Kang, Myung Joo | - |
dc.contributor.author | Choi, Young Wook | - |
dc.date.available | 2019-03-07T04:36:03Z | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 1530-9932 | - |
dc.identifier.issn | 1522-1059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1913 | - |
dc.description.abstract | The objective of this study was to formulate once-a-day extended-release (ER) pellet system of imidafenacin (IDN), a recently approved urinary antispasmodic agent with twice-a-day dosing regimen. The sugar sphere pellets were firstly layered with IDN and hypromellose and then coated with Eudragit RS (copolymers of acrylic and methacrylic acid esters), employed as a release modifier, using a fluid-bed coater. Solid-state characterizations using solid-state X-ray diffraction and differential scanning calorimeter indicated that the antispasmodic agent was homogeneously layered onto the pellets in an amorphous state. Drug release from multiple-unit ER system was effectively retarded in proportion to the amount of Eudragit RS in the outer layer, with a high correlation value above 0.86. In a pharmacokinetic evaluation in beagle dogs, the plasma concentration profile of IDN was markedly protracted by ER pellets, exhibiting delayed the time needed to reach the maximum drug concentration and the elimination half-life in plasma, compared to the commercial immediate release form (UritosA (R) tablet, Kyorin Pharmaceutical Co., Ltd., Japan). Therefore, the novel ER pellets can be a promising tool for oral IDN therapy, providing a once-a-day dosing regimen, and thus, improving patient compliance. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Novel Extended-Release Multiple-Unit System of Imidafenacin Prepared by Fluid-Bed Coating Technique | - |
dc.type | Article | - |
dc.identifier.doi | 10.1208/s12249-018-1100-6 | - |
dc.identifier.bibliographicCitation | AAPS PHARMSCITECH, v.19, no.6, pp 2639 - 2645 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000440308000019 | - |
dc.identifier.scopusid | 2-s2.0-85048830126 | - |
dc.citation.endPage | 2645 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 2639 | - |
dc.citation.title | AAPS PHARMSCITECH | - |
dc.citation.volume | 19 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | imidafenacin | - |
dc.subject.keywordAuthor | multiple-unit dosage form | - |
dc.subject.keywordAuthor | controlled release | - |
dc.subject.keywordAuthor | fluid-bed coating | - |
dc.subject.keywordAuthor | drug release | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordPlus | IN-VIVO EVALUATION | - |
dc.subject.keywordPlus | RS 30 D | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | OVERACTIVE BLADDER | - |
dc.subject.keywordPlus | SUSTAINED-RELEASE | - |
dc.subject.keywordPlus | PELLET SYSTEM | - |
dc.subject.keywordPlus | TABLETS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.